Skip to main content
. 2025 May 7;17(5):621. doi: 10.3390/pharmaceutics17050621

Table 4.

Anti-mycobacterial activity of Nfz and 4-hydroxybenzhydrazone derivatives.

Compound MABA MIC (µg/mL)
Nfz 12.3
Nfz-1 5.1
Nfz-2 18.8
Nfz-3 >100
Nfz-4 >100
Nfz-5 >100
Nfz-6 >100
Nfz-7 98.3
Nfz-8 79.4
Nfz-9 94.1
Nfz-10 47.6
Nfz-11 >100
Nfz-12 >100
Nfz-13 157.8
Nfz-14 >200
Nfz-15 >100
Nfz-16 46.4
Nfz-17 43.6
Nfz-18 186.4
Nfz-19 >100
Nfz-20 >100
Nfz-21 68.7
Nfz-22 >100
Nfz-23 >100
Nfz-24 >100
Nfz-25 45.9
Isoniazid 0.039
Rifampin 0.074
Moxifloxacin 0.184
Linezolid 0.330